The NPS landscape is changing rapidly, requiring laboratories to constantly remain abreast of new and emerging drugs locally, nationally, and internationally. To meet individualized needs, laboratories amend existing methods or develop new ones for detection and confirmation. This can be challenging for scientists as information about NPS detections can be regionalized and/or out-of-date, making it difficult to determine which drugs should be prioritized at a given time. The CFSRE and the SOFT NPS Committee, based in the US, have established recommendations for NPS scope based on information from extensive collaborations, partnerships, and initiatives which yield national perspectives. Quarterly updates are produced.